Apr 28, 2022 / 07:30AM GMT
Operator
Welcome to BioArctic's Q1 Report 2022. Afterwards, there will be a question-and-answer session. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please begin your meeting.
Gunilla Osswald - BioArctic AB(publ)-CEO
Good morning, and welcome to BioArctic's presentation from the first quarter. I'm sorry about the technical issues. I'm Gunilla Osswald, I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson.
I will give an update on lecanemab and some recent highlights in Alzheimer's disease. The Alzheimer's disease field is progressing really well with both lecanemab and some other treatments and with diagnostic tools, such as blood-based biomarkers. I think that it looks very promising for lecanemab. And this year will be very exciting for us with the lecanemab Phase III readout in Alzheimer's disease during the autumn and potentially an accelerated approval in the U.S. And I will talk more about that here today. And of course, I will also mention the recent
Q1 2022 BioArctic AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
